Amedisys (AMED) Hits New 52-Week High and Low at $75.59

Amedisys Inc (NASDAQ:AMED)’s share price reached a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $75.59 and last traded at $75.22, with a volume of 2105 shares trading hands. The stock had previously closed at $73.84.

Several equities analysts recently issued reports on the stock. Craig Hallum boosted their target price on shares of Amedisys from $60.00 to $82.00 and gave the company a “buy” rating in a research note on Wednesday, May 9th. Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research note on Wednesday, May 9th. TheStreet upgraded shares of Amedisys from a “c+” rating to an “a-” rating in a research report on Monday, May 7th. ValuEngine upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Tuesday, May 8th. Finally, Robert W. Baird upped their price objective on shares of Amedisys to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 8th. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Amedisys currently has an average rating of “Buy” and an average target price of $66.90.

The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 33.74, a price-to-earnings-growth ratio of 1.37 and a beta of 0.66.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Monday, May 7th. The health services provider reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.12. The company had revenue of $399.30 million during the quarter, compared to analysts’ expectations of $395.38 million. Amedisys had a net margin of 2.71% and a return on equity of 16.83%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.47 earnings per share. research analysts forecast that Amedisys Inc will post 3.04 EPS for the current fiscal year.

In other news, insider Michael Paul North sold 11,000 shares of the company’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $71.52, for a total transaction of $786,720.00. Following the completion of the sale, the insider now owns 15,206 shares of the company’s stock, valued at $1,087,533.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in AMED. Millennium Management LLC grew its holdings in shares of Amedisys by 58.2% during the fourth quarter. Millennium Management LLC now owns 1,048,423 shares of the health services provider’s stock worth $55,262,000 after buying an additional 385,734 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Amedisys during the fourth quarter worth $8,417,000. Eaton Vance Management grew its holdings in shares of Amedisys by 67.2% during the fourth quarter. Eaton Vance Management now owns 338,488 shares of the health services provider’s stock worth $17,842,000 after buying an additional 136,001 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Amedisys by 6.9% during the fourth quarter. American Century Companies Inc. now owns 1,787,136 shares of the health services provider’s stock worth $94,200,000 after buying an additional 115,456 shares in the last quarter. Finally, Gotham Asset Management LLC grew its holdings in shares of Amedisys by 1,400.0% during the fourth quarter. Gotham Asset Management LLC now owns 108,718 shares of the health services provider’s stock worth $5,731,000 after buying an additional 101,470 shares in the last quarter. 94.07% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply